Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 43, 2007, Pages 17069-17074

  Ebos, John M L ^a,b   Lee, Christina R ^a   Christensen, James G ^c   Mutsaers, Anthony J ^a,b   Kerbel, Robert S ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Angiogenesis; Optimal biological dosing; SU11248; Surrogate biomarkers

Indexed keywords

BEVACIZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; OSTEOPONTIN; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HYPOXEMIA; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CELL HYPOXIA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; MICE; MICE, SCID; NEOPLASMS; ORGAN SPECIFICITY; PREGNANCY PROTEINS; PYRROLES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 36749052895     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0708148104     Document Type: Article

References (32)

1. Woude GF, Kelloff GJ, Ruddon RW, Koo HM, Sigman CC, Barrett JC, Day RW, Dicker AP, Kerbel RS, Parkinson DR, et al. (2004) Clin Cancer Res 10:3897-3907.
2. Kelloff GJ, Bast RC, Jr, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, et al. (2004) Clin Cancer Res 10:3881-3884.
3. Eskens FA, Verweij J (2006) Eur J Cancer 42:3127-3129.
4. Ebos JML, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS (2004) Mol Cancer Res 2:315-326.
5. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, et al. (2005) Ann Oncol 16:558-565.
6. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, Deprimo SE, et al. (2006) J Clin Oncol 24:16-24.
7. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, Deprimo SE, et al. (2007) Clin Cancer Res 13:2643-2650.
8. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, et al. (2006) J Biol Chem 281:951-961.
9. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N (2000) Cancer Res 60:6253-6258.
10. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S, Breed J (2001) J Clin Oncol 19:851-856.
11. Gordon MS, Margolin K, Talpaz M, Sledge GWJ, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) J Clin Oncol 19:843-850.
12. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, et al. (2006) J Clin Oncol 24:25-35.
13. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. (2003) Clin Cancer Res 9:327-337.
14. Faivre S, Demetri G, Sargent W, Raymond E (2007) Nat Rev Drug Discov 6:734-745.
15. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC, Ferrara N (2002) Nature 417:954-958.
16. Mancuso MR, Davis R, Norberg, S. M., O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, et al. (2006) J Clin Invest 116:2610-2621.
17. Casanovas O, Hicklin D, Bergers G, Hanahan D (2005) Cancer Cell 8:299-309.
18. Natori T, Sata M, Washida M, Hirata Y, Nagai R, Makuuchi M (2002) Biochem Biophys Res Commun 297:1058-1061.
19. Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ (2000) Cancer Res 60:6757-6762.
20. Petit I, Jin D, Rafii S (2007) Trends Immunol 28:299-307.
21. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC (2006) Curr Mol Med 6:819-830.
22. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Yung S, Chimenti S, Landsman L, Abramovitch R, Keshet E (2006) Cell 124:175-189.
23. Urbich C, Dimmeler S (2004) Circ Res 95:343-353.
24. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G (2002) Blood 99:2703-2711.
25. Kijowski J, Baj-Krzyworzeka M, Majka M, Reca R, Marquez LA, Christofidou-Solomidou M, Janowska-Wieczorek A, Ratajczak MZ (2001) Stem Cells 19:453-466.
26. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, Failla CM, Zambruno G (2002) J Cell Sci 115:2559-2567.
27. Tan Y, Shao H, Eton D, Yang Z, Alonso-Diaz L, Zhang H, Schulick A, Livingstone AS, Yu H (2007) Cardiovasc Res 73:823-832.
28. Ohki Y, Heissig B, Sato Y, Akiyama H, Zhu Z, Hicklin DJ, Shimada K, Ogawa H, Daida H, Hattori, K. et al. (2005) FASEB J 19:2005-2007.
29. Hirota K, Semenza GL (2006) Crit Rev Oncol Hematol 59:15-26.
30. Peng YJ, Yuan G, Ramakrishnan D, Sharma SD, Bosch-Marce M, Kumar GK, Semenza GL, Prabhakar NR (2006) J Physiol 577:705-716.
31. Bocci G, Man SM, Green SK, Francia G, Ebos, J. M. L., du Manoir JM, Emmenegger U, Ma L, Thorpe P, Davidoff AM, et al. (2004) Cancer Res 64:6616-6625.
32. Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, et al. (2006) Cancer Chemother Pharmacol 57:761-771.